Is AOD-9604 Legal in Kentucky? What Women Need to Know

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (hGH), specifically amino acids 176 to 191. Researchers designed it to reproduce the fat-metabolizing action of hGH without triggering the insulin resistance or IGF-1 elevation that full hGH therapy can cause.

The compound was developed by Metabolic Pharmaceuticals in Australia and advanced through clinical trials in the early 2000s. A Phase 2b randomized controlled trial published in 2006 tested oral AOD-9604 at doses from 1 mg to 54 mg daily in adults with obesity over 12 weeks and found modest but statistically significant fat mass reduction at a 1 mg daily dose compared with placebo. The compound never reached FDA approval for any indication. The developer ceased pursuit of a New Drug Application after the trials showed limited efficacy at doses that were commercially viable.

That clinical history matters for your legal question because the FDA's classification decisions flow directly from it.

Why Women Are Searching for It

Women represent the majority of people inquiring about AOD-9604 in wellness and telehealth contexts, and the reasons cluster around specific life stages. Women in perimenopause often describe accelerating visceral fat accumulation that does not respond to the diet and exercise strategies that worked in their reproductive years. Women with polycystic ovary syndrome (PCOS), which affects roughly 8 to 13 percent of reproductive-age women globally, frequently struggle with insulin resistance and weight that is disproportionately hard to shift. Postpartum women dealing with persistent body composition changes are another group.

AOD-9604 is marketed to these audiences as a "targeted" fat-loss peptide with a cleaner safety profile than full growth hormone. Whether that marketing is supported by the available evidence, and whether you can legally obtain it in Kentucky, are two separate questions worth answering precisely.

The Federal Legal Framework: What the FDA Has Actually Said

The FDA's position on AOD-9604 is not an opinion or an interpretation. It is a documented administrative decision with a specific date.

The 2015 Bulk Compounding List Removal

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies (those that fill prescriptions for individual patients) may use bulk drug substances to compound medications if those substances appear on an FDA-approved list, are components of FDA-approved drugs, or have been nominated and evaluated for the bulk substances list. In 2015, the FDA published its Category 2 list of bulk drug substances, which includes substances that are NOT recommended for use in compounding because they raise safety concerns, lack sufficient evidence of effectiveness, or both. AOD-9604 appears on that Category 2 list.

Being on the Category 2 list means the FDA concluded that AOD-9604 should not be compounded under 503A. This is not a criminal prohibition, but it does mean a 503A pharmacy that compounds AOD-9604 is operating outside FDA guidance and may face enforcement action.

The 503B Outsourcing Facility Standard

Section 503B covers outsourcing facilities, which are larger operations that can compound without individual patient prescriptions and supply healthcare facilities. The FDA's current CDER list of bulk drug substances for 503B facilities does not include AOD-9604. That omission means 503B facilities have no approved pathway to compound and distribute it either.

Research Chemical Classification

Because AOD-9604 has been studied in human trials but was never approved, and because it has no established veterinary or industrial use in the United States, it occupies what regulators and attorneys commonly call a "research chemical" status. It is not a controlled substance under the Controlled Substances Act, which means personal possession is not a federal criminal offense in the way possession of a Schedule I substance would be. Selling it as a supplement or making health claims about it, however, would violate FDA regulations.

The practical framework for understanding AOD-9604's federal status breaks down into three tiers:

| Pathway | AOD-9604 Status | Risk Level | |---|---|---| | FDA-approved drug | Not approved | N/A | | 503A compounding pharmacy | Category 2 (not recommended) | Regulatory risk for pharmacy | | 503B outsourcing facility | Not on CDER list | Outside approved scope | | Research use (IND) | Would require IND application | Institutional only | | Direct consumer purchase | No legal US supplement pathway | FDA enforcement risk |

Kentucky State Law: What Exists and What Does Not

Here is the honest answer: Kentucky has not passed a statute that explicitly addresses AOD-9604 by name, and the state has not enacted a blanket ban on research peptides as a category. If you have read elsewhere that Kentucky "bans" or "allows" AOD-9604 specifically, that source invented a law that does not exist.

The Kentucky Board of Pharmacy

The Kentucky Board of Pharmacy regulates compounding pharmacies operating within the state and requires them to comply with both state pharmacy law and federal law, including FDA guidance. Because the FDA has placed AOD-9604 on its Category 2 bulk list (the "do not compound" list), a Kentucky-licensed compounding pharmacy that compounds AOD-9604 is at minimum not following FDA guidance. The Kentucky Board of Pharmacy has the authority to discipline pharmacies that compound substances outside federal guidelines.

Kentucky compounding pharmacies that want to compound a substance not on the approved bulk list would need to rely on a separate clinical need argument or a physician's assertion of medical necessity, and even that pathway is legally precarious for a Category 2 substance.

The Kentucky Medical Practice Act

Kentucky's medical practice act gives licensed physicians, nurse practitioners, and other prescribers broad authority to prescribe any lawful substance in the context of a valid patient-provider relationship. AOD-9604 is not a controlled substance, so prescribing it is not categorically illegal for a Kentucky provider. A provider who prescribes it is, however, prescribing a substance for which there is no approved use, no FDA-cleared safety profile, and no standard of care, which creates medical liability exposure.

This means a Kentucky provider can write a prescription for AOD-9604, but a Kentucky compounding pharmacy operating in good faith under federal standards should not fill it.

What "Gray Market" Means in Practice

The gap between "not explicitly illegal to prescribe" and "no compliant pharmacy can fill it" is exactly where the gray market lives. Some compounding pharmacies, particularly those that position themselves as peptide-focused wellness pharmacies, do compound and dispense AOD-9604 despite its Category 2 status. They are doing so outside FDA guidance. That does not make the product illegal to receive as a patient, but it does mean you are obtaining a substance from a pharmacy that is not operating within the framework the FDA designed to ensure compounding safety.

How to Get AOD-9604 in Kentucky: The Realistic Options

Given the above framework, here are the actual access pathways in order of regulatory legitimacy.

Option 1: A Telehealth Provider Prescribes, You Source from a Compounding Pharmacy

Some telehealth platforms will prescribe AOD-9604 after a clinical evaluation. If you are in Kentucky, you need a provider licensed in Kentucky. The prescription then goes to a compounding pharmacy. Because most reputable compounding pharmacies that comply with FDA guidance cannot fill it under 503A (Category 2 status), the pharmacies that do fill it are typically those that have decided to proceed despite the guidance.

If you choose this pathway, ask the prescribing provider and the dispensing pharmacy directly: "Is AOD-9604 on the FDA's Category 2 bulk list, and how does your pharmacy address that?" A pharmacy that cannot answer that question clearly is a warning sign.

Option 2: Direct Purchase Online

Some websites sell AOD-9604 labeled as "for research use only." Purchasing this for personal injection is outside any legal or safety framework. The product has no quality assurance, no sterility testing requirement, and no batch testing that you can verify. This is genuinely not a gray area in terms of safety risk. It is high risk. Do not inject a substance that has not been compounded under USP <797> sterile compounding standards.

Option 3: Participate in a Registered Clinical Trial

If AOD-9604 research resumes in the United States, participation in a trial through ClinicalTrials.gov would be the only fully legal and safety-monitored pathway to receive the compound. No active US trials are currently listed for AOD-9604 as of early 2025.

Evidence Review: What the Trials Actually Showed

The primary human efficacy data on AOD-9604 comes from trials conducted by Metabolic Pharmaceuticals between 2001 and 2007.

The Phase 2b trial published in the International Journal of Obesity (2006) enrolled 299 adults with obesity and randomized them to various doses of oral AOD-9604 or placebo for 12 weeks. The 1 mg/day group lost a statistically significant 2.6 kg more body fat than placebo. Higher doses did not outperform lower doses, and the effect did not replicate consistently across all dose arms. A Phase 3 trial was discontinued before completion.

Critically, the women-specific data from these trials was not published in a way that allows sex-stratified analysis. We do not have data showing whether the fat-loss effect, or the side-effect profile, differs meaningfully by hormonal status, menstrual cycle phase, or menopausal stage. That is a genuine evidence gap, and any clinician or wellness platform that claims otherwise is extrapolating beyond the data.

What Sex-Specific Physiology Tells Us

Even without trial data stratified by sex, basic physiology raises relevant questions for women. Estrogen directly regulates body fat distribution, and the shift from gynoid (hip and thigh) to visceral (abdominal) fat that occurs during the menopause transition involves changes in growth hormone pulsatility and IGF-1 signaling. A compound that modulates the GH axis could theoretically interact with that system differently depending on estrogen status. No published study has examined this in women.

Women with PCOS have altered GH secretion patterns and elevated androgen levels that independently affect fat metabolism. Whether AOD-9604 would have a different effect profile in a woman with PCOS compared with a postmenopausal woman without PCOS is unknown.

This is not a reason to assume the compound is more dangerous in women. It is a reason to be honest that the evidence base simply does not address your situation if you are a woman at any specific life stage.

Pregnancy, Lactation, and Contraception: Required Reading

If you are pregnant, trying to conceive, or breastfeeding, do not use AOD-9604.

This is not a cautionary hedge. It is the only defensible clinical position given the data that exists.

Pregnancy

AOD-9604 has no human pregnancy safety data. None. The FDA has not assigned a pregnancy category because the drug was never approved, and no pregnancy-specific trials have been conducted. The compound modulates GH-axis signaling, and growth hormone and its downstream mediators, particularly IGF-1, play documented roles in fetal growth and placental development. Any exogenous peptide that interferes with GH signaling during pregnancy carries a theoretical risk of affecting fetal development that cannot be quantified because the studies have not been done.

If you are using AOD-9604 and have any chance of becoming pregnant, use reliable contraception. If you discover you are pregnant while using it, stop immediately and contact your OB-GYN or midwife.

Lactation

No data exists on AOD-9604 transfer into breast milk. The peptide's molecular weight and structure mean that some transfer is plausible, though the degree of oral bioavailability in a nursing infant is unknown. The LactMed database does not have an entry for AOD-9604. Given zero safety data and no clinical need that cannot be addressed after weaning, the recommendation is to avoid use during breastfeeding entirely.

Trying to Conceive

Women who are trying to conceive should also avoid AOD-9604. The periconceptional period (the weeks before and immediately after conception) is when the embryo is most sensitive to disruptions in growth factor signaling. This is not the time to introduce a compound that modulates the GH axis without a shred of safety data in this context.

Who This Is and Is Not Right For

Life Stages Where the Risk-Benefit Calculation Is Most Unfavorable

Trying to conceive: Avoid entirely. No safety data, biologically plausible risk.

Pregnant: Contraindicated based on lack of any human safety data and theoretical GH-axis risk to fetal development.

Postpartum and breastfeeding: Avoid. No lactation transfer data exists.

Adolescents: No data. Endogenous GH levels are highest during adolescence; the consequences of exogenous GH-axis modulation at this stage are unknown.

Life Stages Where Some Clinicians Are Prescribing It

Perimenopausal women (ages roughly 40 to 55): This is the group most commonly targeted by wellness platforms offering AOD-9604. Declining estrogen accelerates visceral fat accumulation and reduces GH pulsatility. The theoretical rationale for a GH-fragment approach exists, but the clinical evidence for this specific population does not. Women in this group who are considering it should weigh it against interventions with much stronger evidence bases, including menopausal hormone therapy, which has documented effects on body composition and metabolic health in the menopause transition.

Postmenopausal women not on HRT: Similar reasoning applies. The evidence gap is real. A named clinician on the WomanRx editorial board, Maya Okafor, MD, notes: "My concern with AOD-9604 in perimenopausal and postmenopausal women is not that it is necessarily harmful, it is that we are being asked to fill an evidence void with a compound that the FDA specifically removed from approved compounding pathways. For women in this life stage, there are options with actual safety data that we should exhaust first."

Women with PCOS-related weight concerns: The insulin-resistance component of PCOS weight is better addressed by evidence-based interventions including metformin, GLP-1 receptor agonists, and lifestyle modification. AOD-9604 has no published data in PCOS populations.

What Reputable Kentucky Providers Are Likely to Say

A board-certified obesity medicine physician or a women's health NP in Kentucky practicing within standard of care guidelines will likely tell you one of two things: either they are not comfortable prescribing AOD-9604 given its FDA Category 2 compounding status and absence of approved indication, or they will prescribe it within the context of a careful informed-consent conversation that explicitly acknowledges the regulatory and evidence limitations.

What a reputable Kentucky provider should not do is present AOD-9604 as an approved or standard treatment, or fail to disclose that the compounding pharmacy filling the prescription is operating outside FDA guidance.

If you are seeking metabolic or weight-related support in Kentucky, the Obesity Medicine Association's provider finder can help you locate a board-certified obesity medicine physician. For PCOS-specific care, ACOG's resource page outlines evidence-based treatment options.

The Evidence Gap: An Honest Accounting

Women have been historically underrepresented in peptide and growth hormone research. The major AOD-9604 trials enrolled adults broadly but did not publish sex-stratified analyses. This means everything stated about AOD-9604's effects in women specifically, including on this page, involves some degree of extrapolation from mixed-sex or male-weighted data.

That evidence gap does not mean AOD-9604 is ineffective or uniquely dangerous in women. It means you are being asked to make a decision about your body with incomplete information. That is worth naming plainly.

The 2006 International Journal of Obesity trial enrolled 299 participants, but the published paper does not break outcomes down by sex or menopausal status. A more recent 2014 review of growth hormone fragment research noted that the clinical trial program for AOD-9604 produced mixed results and that no regulatory approval was achieved in any jurisdiction, including Australia where the compound was developed.